6 research outputs found
Associating Gender with Neighbourhood Deprivation in Lagos State, Nigeria
No full textAJOL has removed this paper from the website after it was found to be published in another academic publication. AJOL has requestd that both journal editorial boards investigate this matter further with the author
The Prevalence of Cardiovascular Disease in the Lagos State, Nigeria
No full textThe analysis, which examines the prevalence of cardiovascular diseases (ICD 9: 390-459) in Lagos State of Nigeria, was based on records obtained from the register of deaths in four Local Government Areas of the State. The result shows that there is general increase in death rates due to cardiovascular diseases over the five year period (2000- 2004). It was also discovered that the Proportional Mortality Ratio (PMR) for cardiovascular disease was elevated in men (PMR =103; 95% CI= 96 – 110) while there was deficit in female deaths (PMR=98; 95% CI = 91 – 104). The highest cardiovascular death rate was recorded among those in the 60 – 70 years age bracket. The PMR in that group is also the highest (PMR=139; 95% CI=123 – 155) among the various age groups. Data on seven occupational categories show elevated mortality with workers in private sector (PMR=135; 95% CI = 61 – 238) and Civil Servants (PMR=132; 95% CI=109 – 157) recording the highest in that order while highly significant deficit was recorded among students (PMR=76; 95% CI = 60 -95)KEY WORDS: Cardiovascular disease, Gender Differentials, Mortality Rates, Occupational Variability, Life Expectancy Rati
Prevalence and trends in breast cancer in Lagos state, Nigeria
No full textThe study examined the trends in the prevalence of breast cancer in Lagos State, Nigeria. A sample of 1000 subjects was taken from a population consisting of women between the ages of 15 and 60 years spread across the 20 Local Government Areas (LGAs) of the State. Fifty questionnaires were distributed in each LGA. Employing statistical tools such as ANOVA, Chi-Square and that Duncan Multiple Range test, it was found that prevalence of breast cancer differs across age groups with the age range 26 to 45 having the highest prevalence. It was also observed that there is significant difference in prevalence across the years with 2007 recording the highest prevalence. Moreover, the study shows that women’s occupation or profession is important to whether they are diagnosed with breast cancer or not. The study shows steady growth in prevalence of breast cancer over years.Key Words: Psycho-Social, Breast, Cancer, Lagos, Awarenes
Harvard HIV and aging workshop: Perspectives and Priorities from Claude D. Pepper Centers and Centers for AIDS Research
No full textPeople aging with HIV (PAWH) infection experience greater impairments in physical and cognitive function, in addition to higher rates of peripheral comorbid conditions (e.g., renal failure, diabetes, bone fracture, hypertension, cardiovascular disease, polypharmacy, and multimorbidity). While multifactorial drivers, including HIV infection itself, antiretroviral therapy-related toxicities, disparities in care, and biobehavioral factors, likely contribute, there remains an overarching question as to what are the relevant age-related mechanisms and models that could inform interventions that promote health span and life span in PAWH This workshop was convened to hear from experts on the biology of aging and HIV researchers studying PAWH to focus on advancing investigations at the interface of HIV and Aging. In this study, we summarize the discussions from the Harvard Center for AIDS Research and Boston Claude D. Pepper cosponsored workshop on HIV and Aging, which took place in October 2018.http://deepblue.lib.umich.edu/bitstream/2027.42/193070/2/aid.2019.0130.pdfPublished versio
Neuropsychiatric profile of a cohort of perinatally infected HIV positive children after one year of antiretroviral medication
No full textIncludes abstract.Includes bibliographical references.The Highly Active Antiretroviral Therapy (HAART) era in the mid-nineties signalled a dramatic change in the long-term outcome of Human Immunodeficiency Virus (HIV). Many children have shown significant neurologic benefit, and in particular, a decline in the incidence of HIV encephalopathy. As increasing numbers of children have survived into adolescence and early adulthood new challenges have arisen, such as the detection and characterization of milder forms of HIV-associated neurocognitive deficits in children previously thought to be asymptomatic..
The long-term effectiveness of efavirenz-based combination antiretroviral therapy, the impact of pharmacogenomics and pharmacokinetic interaction of artemisinin-based antimalarial therapy on efavirenz exposure among Ghanaian HIV-infected patients
No full textDr. Fred Stephen Sarfo, The long-term effectiveness of efavirenz-based combination antiretroviral therapy, the impact of pharmacogenomics and pharmacokinetic interaction of artemisinin-based antimalarial therapy on efavirenz exposure among Ghanaian HIV-infected patients. PhD dissertation, Durham University, January 2013.
Introduction: In sub-Saharan Africa, HIV treatment is initiated with combination of antiretroviral medications comprising of a backbone of either stavudine or zidovudine plus lamivudine with a non-nucleoside reverse transcriptase inhibitor of either efavirenz or nevirapine. Efavirenz is highly efficacious, durable and well tolerated. The risk for toxicity of efavirenz is determined by several factors including single nucleotide polymorphisms in the hepatic enzymes responsible for its metabolism and concurrently administered medications such as antimalarials, which share common metabolic pathways. The aims of this dissertation are to assess the long-term effectiveness of efavirenz-based antiretroviral therapy and the impact of pharmogenomics and pharmacokinetic interactions of artemisinin-based antimalarial therapy on efavirenz exposure among Ghanaian HIV-infected patients.
Methods: The effectiveness of efavirenz- compared with nevirapine-based antiretroviral therapy was assessed retrospectively in nearly 4000 patients starting treatment between 2004 and 2010. The main outcome measure was a composite of toxicity, disease progression and attrition, and CD4 count changes. A prospective pharmacokinetic study of artesunate and efavirenz was conducted among 22 HIV-infected and 21 controls. Plasma efavirenz and artesunate/ dihydroartemisinin concentrations were measured using validated and standardised methods. Genotyping for single nucleotide polymorphisms in CYP2B6 G516T, T983C; CYP2A6*9B, UGT2B7*735 and *802 as well as CAR rs2307424 were performed for 800 patients with real-time polymerase chain reaction with allelic discrimination.
Results: Antiretroviral therapy was associated with robust CD4 increases. Efavirenz was comparable with nevirapine in composite outcomes but better tolerated. Artesunate was well tolerated when administered to HIV-infected patients on efavirenz. Single nucleotide polymorphisms in the CYP2B6 G516T and T983C were associated with increased plasma efavirenz concentrations.
Conclusions/Recommendation: Among this Ghanaian cohort, both efavirenz and nevirapine-based antiretroviral therapy were effective. The better tolerability of efavirenz compared with nevirapine means it can be safely used as the preferred first line non-nucleoside reverse transcriptase inhibitor in sub-Saharan Africa
